Quiterie Beauregard - MedinCell Head Portfolio
| MDCLF Stock | USD 14.00 7.02 100.57% |
Insider
Quiterie Beauregard is Head Portfolio of MedinCell SA
| Phone | 33 4 67 02 13 67 |
| Web | https://www.medincell.com |
MedinCell Management Efficiency
The company has return on total asset (ROA) of (0.3954) % which means that it has lost $0.3954 on every $100 spent on assets. This is way below average. MedinCell's management efficiency ratios could be used to measure how well MedinCell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MBA | Adaptive Biotechnologies Corp | 50 | |
| Lori CPA | Legend Biotech Corp | 53 | |
| Ying Huang | Legend Biotech Corp | 51 | |
| MBA JD | Apellis Pharmaceuticals | 51 | |
| Lawrence MD | Vir Biotechnology | 77 | |
| Louis MD | Vir Biotechnology | N/A | |
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
| Cedric MD | Apellis Pharmaceuticals | 52 | |
| Klaus Frueh | Vir Biotechnology | 64 | |
| George Scangos | Vir Biotechnology | 76 | |
| Steven Rice | Vir Biotechnology | 64 | |
| Christopher Carlson | Adaptive Biotechnologies Corp | N/A | |
| Howard Horn | Vir Biotechnology | 46 | |
| Yi Zhou | Adaptive Biotechnologies Corp | N/A | |
| Marc Harrison | Legend Biotech Corp | N/A | |
| Kyle Piskel | Adaptive Biotechnologies Corp | 40 | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| Johanna FriedlNaderer | Vir Biotechnology | 56 | |
| Tycho Peterson | Adaptive Biotechnologies Corp | 50 | |
| Nitin Sood | Adaptive Biotechnologies Corp | N/A | |
| Mark Adams | Adaptive Biotechnologies Corp | 57 | |
Management Performance
| Return On Asset | -0.4 |
MedinCell SA Leadership Team
Elected by the shareholders, the MedinCell's board of directors comprises two types of representatives: MedinCell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MedinCell. The board's role is to monitor MedinCell's management team and ensure that shareholders' interests are well served. MedinCell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MedinCell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Richard, Member Board | ||
| Quiterie Beauregard, Head Portfolio | ||
| Helen Martin, Head Management | ||
| Julie Alimi, Head Legal | ||
| Sebastien Enault, Chief Officer | ||
| Christophe Douat, CEO Board | ||
| Jaime Arango, CFO Board | ||
| David Heuze, Head Board | ||
| Adolfo Noriega, Head Board | ||
| Franck Pouzache, Chief Officer |
MedinCell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is MedinCell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 190.33 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.61 % | |||
| Shares Owned By Institutions | 19.00 % | |||
| Price To Book | 34.52 X | |||
| Price To Sales | 31.58 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M |
Currently Active Assets on Macroaxis
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.